Overview

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Status:
Not yet recruiting

Trial end date:
2022-11-04

Target enrollment:

Participant gender:

Summary

This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study

Phase:

Phase 2

Details

Lead Sponsor:

London School of Hygiene and Tropical Medicine

Collaborators:

Janssen Vaccines & Prevention B.V.
University of Sierra Leone